Phase 0/I/II Cancer Prevention Clinical Trials Program Clinical Trials

Titlesort ascending Intervention NCT ID Sponsor Status
Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers Zileuton, Celecoxib, laboratory biomarker analysis NCT01021215 National Cancer Institute (NCI) Completed
Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation cholecalciferol NCT01447355 National Cancer Institute (NCI) Completed
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline NCT02134925 National Cancer Institute (NCI) Active, not recruiting
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive,... Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim NCT02780401 University of Washington Recruiting
Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia Ursodiol, Laboratory Biomarker Analysis NCT01097304 National Cancer Institute (NCI) Completed
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and... metformin hydrochloride NCT01312467 National Cancer Institute (NCI) Completed
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Telapristone Acetate, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration NCT02314156 Northwestern University Active, not recruiting
Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial... Imiquimod, Laboratory Biomarker Analysis, Topical Fluorouracil NCT03196180 National Cancer Institute (NCI) Not yet recruiting
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to... Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate NCT02993159 Northwestern University Recruiting
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma sulindac, placebo, laboratory biomarker analysis NCT00841204 National Cancer Institute (NCI) Completed